bims-microg Biomed News
on Microglia in health and disease
Issue of 2026–02–01
seventeen papers selected by
Marcus Karlstetter, Universität zu Köln



  1. Bioengineering (Basel). 2025 Dec 30. pii: 45. [Epub ahead of print]13(1):
      We present a detailed, xeno-free protocol for the rapid differentiation of human induced pluripotent stem cells (hiPSCs) into microglia using the well-characterized KOLF2.1J reference line. This system employs doxycycline-inducible expression of six transcription factors (6-TF), stably integrated into the CLYBL safe harbor locus, to drive uniform microglial differentiation within two weeks. Building upon an established transcription factor-driven approach, our protocol includes key optimizations for KOLF2.1J, including culture on Laminin-521 to support xeno-free conditions. The resulting i-Microglia exhibit hallmark features of mature microglia, including expression of P2RY12, loss of the pluripotency marker SSEA4, phagocytic activity, and upregulation of immune markers (e.g., CD80, CD83) upon LPS stimulation. We also demonstrate compatibility with co-culture systems using iPSC-derived neurons. Additionally, we describe a modification of the line to include a constitutive mCherry reporter integrated into the SH4-2 safe harbor locus, enabling fluorescent tracking of microglia in mixed cultures or in vivo. This protocol provides a reproducible and scalable platform for generating functional human microglia from a widely used hiPSC line, supporting applications in brain tumors and disease modeling, neuroinflammation research, and therapeutic screening.
    Keywords:  differentiation; induced pluripotent stem cells; microglia
    DOI:  https://doi.org/10.3390/bioengineering13010045
  2. Neuroscience. 2026 Jan 23. pii: S0306-4522(26)00063-1. [Epub ahead of print]
      Although upregulation of toll-like receptor 2 (TLR2) excessively activates pro-inflammatory microglia through Aβ peptides, it remains unclear whether TLR2 regulates neuronal pyroptosis via the NF-κB/NLRP3 pathway in Alzheimer's disease (AD). We assessed TLR2 expression in peripheral blood from clinical samples and employed SH-SY5Y cells for initial screening. AD pathology was simulated by Aβ1-42 stimulation, and pathway regulatory relationships were dissected through TLR2 knockdown, NF-κB overexpression, and NLRP3 activation experiments. APP/PS1 mice were treated with sh-TLR2. Results demonstrated that high TLR2 expression activated the NF-κB/NLRP3 pathway and promoted pyroptosis, while TLR2 silencing suppressed Aβ1-42-driven pyroptosis in SH-SY5Y cells by inhibiting this pathway. NF-κB overexpression or NLRP3 activation partially reversed the protective effect of TLR2 silencing. In vivo experiments confirmed the role of TLR2 knockdown in AD mice. Thus, this study revealed that TLR2 drives neuronal pyroptosis via the NF-κB/NLRP3 pathway, providing a novel therapeutic target for AD. These findings complements existing microglia-centered TLR2 research and broadens the understanding of neuroinflammatory regulation. However, SH-SY5Y cells differ from primary neurons in maturity, which may limit mechanistic extrapolation. Further validation in induced pluripotent stem cells-derived primary neurons or humanized mouse models will enhance the clinical translational potential of these findings.1-421-421-42.
    Keywords:  Alzheimer’sdisease; NOD-, LRR- and pyrin domain-containing 3; Nuclear factor kappa B; Pyroptosis; Toll-like receptor 2
    DOI:  https://doi.org/10.1016/j.neuroscience.2026.01.026
  3. Brain Behav Immun Health. 2026 Mar;52 101168
      Women affected by obstructive sleep apnea (OSA) face an increased risk of cognitive impairment and mood disorders, with emerging evidence suggesting that neuroinflammation plays a significant role in the pathophysiology. OSA causes intermittent hypoxia and activates the immune response in the brain. Additionally, menopause is a separate risk factor that can put women with OSA at an even higher risk of cognitive decline. Although neuroinflammation occurs in OSA, the underlying mechanisms of the neuroinflammatory response are not well understood, and it remains unknown whether ovarian hormones modify these mechanisms. To examine the impact of OSA and hormone status on neuroinflammation, we used a 7-day chronic intermittent hypoxia (CIH) and ovariectomy (OVX) to model OSA and hormone status in female rats, respectively. To examine neuroinflammation, we investigated changes in brain microglia and astrocyte morphology and the number of reactive cells. We used a comprehensive three-dimensional reconstruction and analysis of microglia and astrocytes to study the changes in the morphology of these cells. We focused on brain regions associated with cognitive function (CA1 of the dorsal hippocampus, medial prefrontal cortex - mPFC, caudate and putamen - CP). Specifically, immunofluorescence of Iba1 (microglia marker) and GFAP (astrocyte marker) was conducted, along with measuring indicators of glial reactivity (branching, complexity, cell size, and number of reactive cells). Our results found that there were CIH and hormone effects on neuroinflammation in these brain regions. Microglia activation was impacted by an interaction between CIH and hormone status in all regions examined. In contrast, astrocytes showed no reactivity in all regions examined, regardless of CIH or hormone status. These findings suggest that menopause and OSA may impact microglia remodeling in brain areas associated with cognitive function. Microglia-specific neuroinflammation may be part of early mechanisms that lead to the cognitive impairments observed in CIH and hormone loss in females.
    Keywords:  Astrocytes; Chronic intermittent hypoxia; Cognitive function; Microglia; Neuroinflammation; Ovarian hormones
    DOI:  https://doi.org/10.1016/j.bbih.2026.101168
  4. iScience. 2026 Feb 20. 29(2): 114526
      Uveitis is a sight-threatening intraocular inflammation in which the proinflammatory immune response driven by retinal microglia is a key contributor. Proteolysis targeting chimera (PROTAC) targeting bromodomain and extraterminal (BET) proteins has shown therapeutic effects in certain inflammatory diseases or tumors, but their effects on uveitis remain elusive. Our research demonstrated that PROTAC D072 reduced intraocular inflammation in vivo and inhibited proinflammatory microglia in both uveitis retina and lipopolysaccharide (LPS) treated mouse microglia cell line BV2. Drug target verification revealed that D072 specifically degraded BRD3 but did not significantly affect BRD2 or BRD4. Mechanistically, BRD3 degradation resulted in reduced H3K18ac, and CUT&Tag analysis revealed changes in the occupancy of several proinflammatory and metabolism-related genes. Furthermore, histone deacetylases (HDACs) partially regulate the H3K18ac level following BRD3 degradation. Overall, we identified D072 as a specific degrader of BRD3 in the murine system that can inhibit proinflammatory microglia in autoimmune uveitis, potentially providing a therapeutic approach for uveitis.
    Keywords:  Biological sciences; Epigenetics; Ophthalmology
    DOI:  https://doi.org/10.1016/j.isci.2025.114526
  5. Mol Neurobiol. 2026 Jan 30. 63(1): 408
      Damage following ischemic stroke is worsened by microglial activation and subsequent neuroinflammation. Polypyrimidine tract binding protein 2 (Ptbp2) can influence the chemotaxis and repolarization of cancer-related macrophages; however, its specific role in microglial polarization and the underlying mechanisms are not yet fully understood. This study aimed to elucidate the neuroprotective mechanisms of Ptbp2 and examine its effects on microglial activation, neuroinflammation, and glucose metabolism following cerebral ischemia. Mice model of ischemic stroke was developed using temporary middle cerebral artery occlusion (tMCAO). Adeno-associated viruses were used for overexpression and knockdown in C57 mice, and microglial polarization, blood-brain barrier (BBB) integrity, and glycolytic parameters in the peri-infarct cortex were evaluated. RNA sequencing (RNA-seq) was performed on mouse brain tissues. To investigate the underlying mechanisms, the mouse brain microvascular endothelial cell line bEnd.3 and BV2 microglial cell line were used. The protective effect of Ptbp2 on BBB integrity following stroke was evaluated by targeted overexpression and knockdown. We found that Ptbp2 overexpression reduced microglia-mediated neuroinflammation and BBB damage while inhibiting pathological glycolysis, according to findings from both in vitro and in vivo studies. Additionally, Ptbp2 level was significantly downregulated in patients with stroke compared to controls, and was inversely correlated with the severity of neural impairment. Our study unveils novel immunomodulatory mechanisms in stroke and highlights Ptbp2 and its regulatory network as potential therapeutic targets for stroke.
    Keywords:  Blood–brain barrier; Glycolysis; Ischemic stroke; Microglial polarization; NF-κB; Neuroinflammation; Ptbp2
    DOI:  https://doi.org/10.1007/s12035-026-05704-3
  6. Life Sci. 2026 Jan 27. pii: S0024-3205(26)00049-4. [Epub ahead of print] 124241
      One of the main causes of vision impairment in diabetics is diabetic retinopathy (DR). However, the molecular mechanisms controlling its progression remains incompletely known. In this research, we identified the STAT1/SLC31A1 signaling pathway as a key regulator of cuproptosis-induced M1 polarization in microglial cells, thereby contributing to the pathogenesis of DR. STAT1 expression was markedly elevated under settings of high glucose (HG), both in in vitro experiments and in streptozotocin (STZ)-induced diabetic mouse models. Mechanistically, STAT1 transcriptionally upregulated the copper transporter SLC31A1, leading to copper accumulation and enhanced cuproptosis, as indicated by decreased levels of L-DLAT, FDX1, and NDUFS8. This cellular stress promoted M1 polarization and increased the expression of pro-inflammatory cytokines. Inhibition of either STAT1 or SLC31A1 significantly attenuated HG-induced cuproptosis and microglial activation. In vivo, STAT1 inhibition reduced retinal inflammation and structural damage, supporting its pathological role in DR progression. These findings confirm that the STAT1/SLC31A1/cuproptosis axis is a critical driver of microglial polarization and retinal injury and imply that SLC31A1 may act as DR's potential therapeutic target.
    Keywords:  Cuproptosis; Diabetic retinopathy; M1 polarization; Microglial cells; SLC31A1; STAT1
    DOI:  https://doi.org/10.1016/j.lfs.2026.124241
  7. Front Immunol. 2025 ;16 1700998
      Normal-tension glaucoma (NTG) is a subtype of primary open-angle glaucoma (POAG). Patients with NTG still experience significant optic nerve damage despite maintaining normal intraocular pressures. The mechanism of optic nerve damage in glaucoma with normal pressure is still unclear. Research has shown that OPTN (E50K) mutations exacerbate the inflammatory response of retinal microglia. However, there is still a lack of evidence on how OPTN (E50K) mutations directly regulate their inflammatory pathways through key molecules. This study explores the role of microglial inflammation caused by the interaction between IRF7 and NLRP3 molecules in NTG optic nerve injury. Single-cell RNA sequencing (scRNA-seq) was employed to analyze retinal microglial cells from both wild-type (WT) and OPTN (E50K) mutant mice. The analysis revealed significant enrichment of inflammatory pathways and a critical role of IRF7 in modulating NLRP3 activation. Techniques such as Western blot (WB), qPCR, immunofluorescence (IF), and molecular docking were utilized to confirm the interactions between IRF7 and NLRP3. The findings demonstrate that the OPTN (E50K) mutation reduces the suppressive effect of IRF7 on NLRP3, leading to a pro-inflammatory microglial phenotype and exacerbating the optic nerve damage of NTG. This study provides a new therapeutic target for the treatment of NTG optic nerve damage.
    Keywords:  IRF7; NLRP3; OPTN (E50K) mutation; microglia; normal-tension glaucoma; optic nerve damage; single-cell RNA sequencing
    DOI:  https://doi.org/10.3389/fimmu.2025.1700998
  8. Front Immunol. 2025 ;16 1717319
      Intracerebral hemorrhage (ICH) triggers devastating secondary brain injury driven by maladaptive microglial activation and neuroinflammation. While N6-methyladenosine (m6A) RNA methylation influences inflammation, its spatiotemporal regulation in ICH microglia remains unclear. Here, we identified METTL3 as a key epigenetic driver that promotes neuropathology post-ICH. Our analyses revealed that upregulated METTL3 expression in activated microglia in ICH model mice was correlated with increased global m6A levels. Functional studies have demonstrated that METTL3 depletion attenuates the release of proinflammatory cytokines (TNF-α, IL-1β, and IL-6), suppresses NF-κB activation, and reduces apoptosis in microglia. Mechanistically, MeRIP-seq and RNA-seq identified the transcription factor ETV4 as a METTL3 target, where METTL3-mediated m6A modification of the ETV4 3'-UTR recruits the reader IGF2BP2 to increase mRNA stability. This axis drives NF-κB-mediated inflammation and caspase-3-dependent apoptosis. Overall, our work reveals the role of METTL3 in sustaining neuroinflammation and inducing apoptosis via m6A/ETV4 stabilization and suggests that METTL3 inhibition is a promising strategy for ameliorating ICH injury.
    Keywords:  Etv4; METTL3; apoptosis; m6A modification; neuroinflammation
    DOI:  https://doi.org/10.3389/fimmu.2025.1717319
  9. Elife. 2026 Jan 27. pii: RP102900. [Epub ahead of print]14
      Microglia, the brain's resident macrophages, can be reconstituted by surrogate cells - a process termed 'microglia replacement'. To expand the microglia replacement toolkit, we here introduce estrogen-regulated (ER) homeobox B8 (Hoxb8) conditionally immortalized macrophages, a cell model for generation of immune cells from murine bone marrow, as a versatile model for microglia replacement. We find that ER-Hoxb8 macrophages are highly comparable to primary bone marrow-derived macrophages in vitro, and, when transplanted into a microglia-free brain, engraft the parenchyma and differentiate into microglia-like cells. Furthermore, ER-Hoxb8 progenitors are readily transducible by virus and easily stored as stable, genetically manipulated cell lines. As a demonstration of this system's power for studying the effects of disease mutations on microglia in vivo, we created stable, Adar1-mutated ER-Hoxb8 lines using CRISPR-Cas9 to study the intrinsic contribution of macrophages to Aicardi-Goutières syndrome (AGS), an inherited interferonopathy that primarily affects the brain and immune system. We find that Adar1 knockout elicited interferon secretion and impaired macrophage production in vitro, while preventing brain macrophage engraftment in vivo - phenotypes that can be rescued with concurrent mutation of Ifih1 (MDA5) in vitro, but not in vivo. Lastly, we extended these findings by generating ER-Hoxb8 progenitors from mice harboring a patient-specific Adar1 mutation (D1113H). We demonstrated the ability of microglia-specific D1113H mutation to drive interferon production in vivo, suggesting microglia drive AGS neuropathology. In sum, we introduce the ER-Hoxb8 approach to model microglia replacement and use it to clarify macrophage contributions to AGS.
    Keywords:  immunology; inflammation; leukodystrophies; microglia; microglia replacement; mouse; neuroscience
    DOI:  https://doi.org/10.7554/eLife.102900
  10. J Nanobiotechnology. 2026 Jan 30.
      Traumatic brain injury (TBI)-induced neuroinflammation, driven by inflammatory microglial polarization, continues to pose a significant regenerative and clinical challenge. Small extracellular vesicles (sEVs) have demonstrated great potential in mitigating post-TBI inflammation. Nevertheless, the limited yield and efficacy of sEVs produced via conventional two-dimensional (2D) culture systems (2D-sEVs) substantially hinder their clinical applicability. Moreover, effective strategies for the therapeutic application of sEVs in TBI treatment, along with an understanding of their underlying mechanisms, remain largely unexplored. In this study, we employed a 3D coaxial bioprinting method to encapsulate adipose-derived stem cells (ADSCs) within a hydrogel microfiber, facilitating 3D culturing and large-scale production of 3D-sEVs. Additionally, we utilized GelMA hydrogel for the sustained release of 3D-sEVs and evaluated their effects in LPS-activated microglia as well as in a TBI mouse model. Our results demonstrated that 3D culture significantly enhanced sEV production. GelMA improved sEV stability and prolonged sEV release up to 30 days in vivo. Compared to 2D-sEVs, 3D-sEVs offered superior therapeutic benefits. Specifically, 3D-sEVs substantially reduced neuroinflammation and brain tissue loss while accelerating motor function recovery in TBI mice. Furthermore, 3D-sEVs shifted pro-inflammatory microglia toward an anti-inflammatory polarization state, as evidenced by elevated expression levels of IL-4, IL-10, TGF-β, Arg1, and CD206, alongside reduced expression of IL-6, IL-1β, TNF-α, iNOS, and CD86, both in vitro and in vivo. Additionally, 3D-sEVs attenuated chemotaxis and migration in LPS-activated microglia. Further mechanistic exploration through RNA-seq, proteomic profiling, and GAS6 knockdown in 3D-sEVs, revealed that 3D-sEVs deliver growth arrest-specific protein 6 (GAS6) to modulate the transition of microglia from a pro-inflammatory to an anti-inflammatory state, thereby mitigating neuroinflammation following TBI. Our findings underscore the therapeutic promise of sEVs derived from 3D-cultured ADSCs in treating TBI via modulating microglia polarization.
    Keywords:  Bioprinting; GAS6; Microglia polarization; Small extracellular vesicles (sEVs); Traumatic brain injury
    DOI:  https://doi.org/10.1186/s12951-026-04064-3
  11. Adv Sci (Weinh). 2026 Jan 28. e19642
      Neuroinflammation is a critical driver of epileptogenesis and cognitive dysfunction in epilepsy; however, targeted anti-inflammatory therapies remain limited. In this study, we demonstrate that microglial GPR35 orchestrates neuroinflammatory epileptic networks through platelet-derived growth factor A (PDGFA)-dependent signaling. Single-nucleus RNA sequencing of patients with temporal lobe epilepsy (TLE) and pharmacological models reveals selective GPR35 upregulation in disease-associated microglia. GPR35 deficiency exacerbates seizure susceptibility and cognitive deficits. We further demonstrate that GPR35 activation mitigates seizures, suppresses hippocampal neuroinflammation, and alleviates cognitive deficits. Mechanistically, kynurenic acid-activated GPR35 specifically interacts with PDGFA domain 2 via defined binding motifs, thereby suppressing PDGFA degradation through the ubiquitin-proteasome pathway. This cascade triggers PI3K-AKT signaling and subsequently inhibits pro-inflammatory responses. Conversely, GPR35 deficiency disrupts this pathway of neuroinflammation, and hyperexcitability. PDGFA overexpression phenocopies GPR35 activation, attenuating inflammation and epileptogenesis. These findings establish GPR35 as a critical modulator of epileptic networks via PDGFA-dependent anti-inflammatory signaling, bridging neuroimmune crosstalk with the pathophysiology of epilepsy. Our study identifies GPR35 as a druggable target capable of disrupting the vicious cycle of inflammation and hyperexcitability in epilepsy, offering a dual therapeutic strategy to alleviate seizures and cognitive comorbidities.
    Keywords:  GPR35; PDGFA; epileptogenesis; kynurenic acid; neuroinflammation
    DOI:  https://doi.org/10.1002/advs.202519642
  12. Adv Sci (Weinh). 2026 Jan 25. e11482
      White matter stroke (WMS) results in demyelinating changes and neurological deficits. However, the underlying molecular mechanisms of demyelination after stroke and the specific role of microglia in white matter rehabilitation remain incompletely elucidated. This study identifies a time-dependent accumulation of iron in microglial lysosomes mediated by solute carrier family 11 member 1 (SLC11A1), which persists from 12 h to 14 days following WMS. This iron accumulation results in damaged lysosomal myelin debris uptake and degradation in microglia. Notably, iron chelation with deferoxamine (DFO), microglia-specific knockdown of SLC11A1, and administration of LM22B-10, a SLC11A1 antagonist identified in this study, effectively reduce lysosomal iron accumulation in microglia, enhance microglial uptake and clearance of myelin debris, and ultimately promote functional recovery after WMS. Furthermore, SLC11A1 functions as a H+/Fe2+ antiporter that transports Fe2+ from the cytoplasm into lysosomes both in vitro and in vivo. Collectively, these results highlight that targeting SLC11A1 represents a previously unrecognized therapeutic strategy for WMS repair with significant clinical implications.
    Keywords:  iron accumulation; lysosomes; microglia; solute carrier family 11 member 1(SLC11A1), white matter stroke(WMS)
    DOI:  https://doi.org/10.1002/advs.202511482
  13. Nat Commun. 2026 Jan 24.
      Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer's disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in microglia, we generated a TREM2 reporter mouse. In APP transgenic animals, bulk RNA-sequencing of isolated microglia sorted based on reporter expression highlighted TREM2 level-related changes in major immunometabolic pathways, and enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. Metabolic and lipidomic profiling of sorted microglia showed that, independent of Aβ pathology, TREM2 expression correlated with signatures consistent with increased cellular redox, energetics, and cholesterol homoeostasis. In accordance, metabolic activity correlated with phagocytic capacity. Finally, we performed chronic treatment with a TREM2 agonist antibody and identified a window of TREM2 expression where microglia are most responsive, thereby informing clinical applications of TREM2 agonists.
    DOI:  https://doi.org/10.1038/s41467-026-68706-8
  14. Brain Behav Immun. 2026 Jan 22. pii: S0889-1591(26)00043-7. [Epub ahead of print] 106295
      Secondary spinal cord injury (SCI) involves neuroinflammatory mechanisms such as microglial pyroptosis, which aggravates neural impairment via NLRP3 inflammasome activation. Although liraglutide (Lr) is commonly used for managing blood glucose, it also exhibits anti-inflammatory effects. Previous studies from our group have shown that glucagon-like peptide-1 receptor (GLP-1R) activation in microglia attenuates neuroinflammation and promotes functional recovery after SCI, the precise mechanism linking GLP-1R to the inhibition of pyroptosis remained unclear. Here, we report that high-dose Lr (independent of its metabolic effects) significantly improves functional and histological outcomes in a murine SCI model, and these benefits are abolished in GLP-1R-/- mice. In vitro, RNA sequencing, combined with pharmacological and genetic approaches, revealed that Lr, via the PI3K/Akt/transcription factor EB (TFEB) axis, by upregulates Fanconi anemia complementation group C (FANCC) to suppress pyroptosis. Crucially, FANCC knockdown both elevated p38 phosphorylation and blocked the anti-pyroptotic effect of Lr, thereby establishing FANCC as an essential downstream mediator. This signaling cascade culminates in the inhibition of p38-dependent NLRP3 inflammasome activation. Collectively, our work defines a novel GLP-1R/PI3K/Akt/TFEB/FANCC/p38 pathway through which Lr alleviates secondary SCI, identifying FANCC as a pivotal neuroprotective node and supporting the translational potential of GLP-1R modulation in SCI.
    Keywords:  FANCC; GLP-1R; Microglia; Pyroptosis; Spinal cord injury
    DOI:  https://doi.org/10.1016/j.bbi.2026.106295